Humacyte (NASDAQ:HUMA – Get Free Report) and Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.
Risk and Volatility
Humacyte has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.
Earnings and Valuation
This table compares Humacyte and Scinai Immunotherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Humacyte | $2.04 million | 80.34 | -$40.83 million | ($0.49) | -1.20 |
| Scinai Immunotherapeutics | $1.49 million | 0.44 | -$8.31 million | $8.66 | 0.06 |
Scinai Immunotherapeutics has lower revenue, but higher earnings than Humacyte. Humacyte is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 3.1% of Humacyte shares are owned by company insiders. Comparatively, 6.0% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Humacyte and Scinai Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Humacyte | -4,556.29% | -983.32% | -88.84% |
| Scinai Immunotherapeutics | N/A | N/A | N/A |
Analyst Ratings
This is a summary of recent ratings for Humacyte and Scinai Immunotherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Humacyte | 1 | 1 | 6 | 0 | 2.62 |
| Scinai Immunotherapeutics | 1 | 0 | 0 | 0 | 1.00 |
Humacyte currently has a consensus target price of $4.96, suggesting a potential upside of 741.40%. Given Humacyte’s stronger consensus rating and higher possible upside, analysts plainly believe Humacyte is more favorable than Scinai Immunotherapeutics.
Summary
Scinai Immunotherapeutics beats Humacyte on 8 of the 14 factors compared between the two stocks.
About Humacyte
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for use in regenerative medicine and vascular repair. The company’s platform is designed to create implantable, off-the-shelf tissues that can be stored and used when needed without requiring the collection of tissue from the patient. Its primary product is SYMVESS, an acellular tissue-engineered vessel intended to replace or repair damaged blood vessels. In December 2024, the U.S. Food and Drug Administration approved SYMVESS for use in the urgent treatment of extremity arterial injuries when emergency vascular reconstruction is required.
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
